Briguori, et al C&CI 2020
Contrast-Induced Acute Kidney Injury (AKI) also known as Contrast-Induced Nephropathy (CIN) is a major and growing problem. A significant percentage of cath lab patients are at risk for AKI. And the consequences are severe, both clinically and financially.1
Increased 30-Day
Readmission
Per CKD Patient
Increased Length of Stay
Increased In-Hospital
Mortality
The DyeVert™ System is a simple solution to prevent AKI
Demonstrated effective
in preventing AKI in high-risk patients2‑9
Consistent reduction
of delivered contrast averaging 40%10
Easy-to-use
integrates seamlessly into coronary and peripheral angiography procedures
Patients with Chronic Kidney Disease (CKD) are at high risk for AKI. But they’re not the only ones. A broad range of conditions commonly seen in cath labs elevate AKI risk. When you’re treating these patients, the DyeVert System provides the critical kidney protection they need.
Reducing AKI risk in multiple patient populations in a San Antonio hospital
How an Austin cath lab reduced AKI incidence from 12% to 2%
How AKI-reduction protocols support the quality-first mission of a rural Mississippi hospital
Covid accelerates a Houston cath lab’s drive to prevent readmissions due to AKI
About
Osprey Medical
Clinical Abstracts & Publications
DyeVert
Presentations
© 2021 Osprey Medical Inc. All rights reserved.
Osprey Medical, DyeVert, DyeMINISH, and Be Kind to Kidneys are registered Trademarks of Osprey Medical, Inc. in the United States and other countries.
